<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00835627</url>
  </required_header>
  <id_info>
    <org_study_id>EF122982</org_study_id>
    <nct_id>NCT00835627</nct_id>
  </id_info>
  <brief_title>Treatment Trial for Psychogenic Nonepileptic Seizures</brief_title>
  <acronym>NEST-T_1</acronym>
  <official_title>Medication and Psychotherapy Treatment Trial for Psychogenic Nonepileptic Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhode Island Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Epilepsy Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Epilepsy Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rhode Island Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose that patients who receive targeted pharmacotherapy (sertraline) or
      focused psychotherapy (cognitive behavioral therapy-informed psychotherapy (CBT-ip) for NES)
      or combined treatment (CBT-ip + sertraline) will report fewer nonepileptic seizures (NES)
      compared to patients who receive community care / treatment as usual (TAU). The purpose of
      this study is to provide pilot testing and data to inform the future multicenter randomized
      controlled trial based on the hypothesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot, prospective, multi-center, randomized controlled trial, that assesses the
      number of NES in patients treated with either flexible dose sertraline (Zoloft), cognitive
      behavioral therapy-informed psychotherapy (CBT-ip), combined therapy (sertraline + CBT-ip) or
      community care (treatment as usual TAU). This study will provide outcomes data and the effect
      size necessary for a future R01, multi-center randomized control trial. Secondary objective
      variables include reduction in depression, anxiety, impulsivity scores, and improvement in
      psychosocial functioning.

      After being diagnosed with NES by video EEG monitoring (vEEG), up to 40 participants will be
      enrolled and monitored during a two week lead in period for their baseline NES and
      psychosocial symptoms and functioning. At week 2, they will be randomized to either: flexible
      dose sertraline (25 to 200mg), CBT, CBT+med, or to the control arm, TAU. Participants
      randomized to the sertraline arm will be titrated over 6 weeks up to 200mg or to dose limited
      by side effects. The subjects will stay on their maximum fixed dose for the next 4 weeks. At
      week 10, the subjects may elect to remain on the sertraline or they can taper off the
      medication over the final two weeks of the treatment trial. Those randomized to the CBT-ip
      arm will receive 12 weekly sessions of CBT-ip for NES. Those randomized to the CBT-ip + med
      arm will receive both treatments. Those randomized to the TAU arm will follow with their
      treatment providers.

      After the treatment trial, the subjects will have follow up phone calls at month 4, 8, and 12
      after enrollment to assess seizure status, medication usage, and global functioning.

      Upon enrollment, subjects will be evaluated with a structured psychiatric and neurological
      exam, and with bi-weekly, 30 to 60 minute appointments where they will complete symptom and
      function scales. They will keep a seizure diary to evaluate their daily seizure activity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>seizure frequency</measure>
    <time_frame>weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify predictors of response from the following 3 groups: clinical diagnoses</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>psychological symptoms</measure>
    <time_frame>bi-weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>socio-demographic variables</measure>
    <time_frame>bi-weekly</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Convulsion, Non-Epileptic</condition>
  <condition>Conversion Disorder</condition>
  <condition>Depression</condition>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <condition>Dissociative Disorders</condition>
  <arm_group>
    <arm_group_label>sertraline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>flexible dose sertraline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBT-ip</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual, 1 hour therapy sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined (sertraline + CBT-ip)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12 individual, 1 hour therapy sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>community care / treatment as usual: routine follow up with existing providers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sertraline</intervention_name>
    <description>flexible dose sertraline</description>
    <arm_group_label>sertraline</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBT-ip</intervention_name>
    <description>cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual 1 hour therapy sessions</description>
    <arm_group_label>CBT-ip</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Combined (sertraline + CBT-ip)</intervention_name>
    <description>flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12, individual 1 hour therapy sessions</description>
    <arm_group_label>Combined (sertraline + CBT-ip)</arm_group_label>
    <other_name>Zoloft</other_name>
    <other_name>CBT-ip</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <description>community care, treatment as usual: routine follow up with existing providers</description>
    <arm_group_label>Standard care</arm_group_label>
    <other_name>TAU, standard care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Video electroencephalogram (EEG) confirmed diagnosis of NES

          -  Have at least one nonepileptic seizure per month

          -  Able to complete self report symptom scales

          -  Not receiving optimized sertraline

        Exclusion Criteria:

          -  Equivocal EEG findings

          -  using monoamine oxidase inhibitors (MAOIs), pimozide, or sumatriptan

          -  allergy/sensitivity to sertraline

          -  current alcohol/drug dependence

          -  serious medical illness requiring current hospitalization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. Curt LaFrance, Jr., MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rhode Island Hospital / Brown Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ninds.nih.gov/news_and_events/proceedings/2005_nonepileptic_seizures.htm</url>
    <description>NINDS/NIMH/AES NES Treatment Workshop</description>
  </link>
  <reference>
    <citation>LaFrance WC. How many patients with psychogenic nonepileptic seizures also have epilepsy? Neurology. 2002 Mar 26;58(6):990; author reply 990-1.</citation>
    <PMID>11914432</PMID>
  </reference>
  <reference>
    <citation>LaFrance WC Jr, Devinsky O. Treatment of nonepileptic seizures. Epilepsy Behav. 2002 Oct;3(5 Suppl):19-23.</citation>
    <PMID>12609316</PMID>
  </reference>
  <reference>
    <citation>LaFrance WC Jr, Devinsky O. The treatment of nonepileptic seizures: historical perspectives and future directions. Epilepsia. 2004;45 Suppl 2:15-21. Review.</citation>
    <PMID>15186340</PMID>
  </reference>
  <reference>
    <citation>LaFrance WC Jr, Barry JJ. Update on treatments of psychological nonepileptic seizures. Epilepsy Behav. 2005 Nov;7(3):364-74. Epub 2005 Sep 16. Review.</citation>
    <PMID>16150653</PMID>
  </reference>
  <reference>
    <citation>LaFrance WC Jr, Alper K, Babcock D, Barry JJ, Benbadis S, Caplan R, Gates J, Jacobs M, Kanner A, Martin R, Rundhaugen L, Stewart R, Vert C; NES Treatment Workshop participants. Nonepileptic seizures treatment workshop summary. Epilepsy Behav. 2006 May;8(3):451-61. Epub 2006 Mar 15.</citation>
    <PMID>16540377</PMID>
  </reference>
  <reference>
    <citation>LaFrance WC Jr. Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 25;66(8):1287-8; author reply 1287-8.</citation>
    <PMID>16636265</PMID>
  </reference>
  <reference>
    <citation>LaFrance WC Jr, Benbadis SR. Avoiding the costs of unrecognized psychological nonepileptic seizures. Neurology. 2006 Jun 13;66(11):1620-1.</citation>
    <PMID>16769930</PMID>
  </reference>
  <reference>
    <citation>LaFrance WC Jr, Blum AS, Miller IW, Ryan CE, Keitner GI. Methodological issues in conducting treatment trials for psychological nonepileptic seizures. J Neuropsychiatry Clin Neurosci. 2007 Fall;19(4):391-8.</citation>
    <PMID>18070841</PMID>
  </reference>
  <reference>
    <citation>LaFrance WC Jr, Rusch MD, Machan JT. What is &quot;treatment as usual&quot; for nonepileptic seizures? Epilepsy Behav. 2008 Apr;12(3):388-94. doi: 10.1016/j.yebeh.2007.12.017. Epub 2008 Feb 20.</citation>
    <PMID>18282812</PMID>
  </reference>
  <reference>
    <citation>LaFrance WC Jr. Psychogenic nonepileptic seizures. Curr Opin Neurol. 2008 Apr;21(2):195-201. doi: 10.1097/WCO.0b013e3282f7008f. Review.</citation>
    <PMID>18317280</PMID>
  </reference>
  <reference>
    <citation>LaFrance WC Jr, Baker GA, Duncan R, Goldstein LH, Reuber M. Minimum requirements for the diagnosis of psychogenic nonepileptic seizures: a staged approach: a report from the International League Against Epilepsy Nonepileptic Seizures Task Force. Epilepsia. 2013 Nov;54(11):2005-18. doi: 10.1111/epi.12356. Epub 2013 Sep 20. Review.</citation>
    <PMID>24111933</PMID>
  </reference>
  <reference>
    <citation>LaFrance WC Jr, Reuber M, Goldstein LH. Management of psychogenic nonepileptic seizures. Epilepsia. 2013 Mar;54 Suppl 1:53-67. doi: 10.1111/epi.12106. Review.</citation>
    <PMID>23458467</PMID>
  </reference>
  <reference>
    <citation>LaFrance WC Jr, Deluca M, Machan JT, Fava JL. Traumatic brain injury and psychogenic nonepileptic seizures yield worse outcomes. Epilepsia. 2013 Apr;54(4):718-25. doi: 10.1111/epi.12053. Epub 2013 Jan 2.</citation>
    <PMID>23281644</PMID>
  </reference>
  <reference>
    <citation>LaFrance WC Jr, Alosco ML, Davis JD, Tremont G, Ryan CE, Keitner GI, Miller IW, Blum AS. Impact of family functioning on quality of life in patients with psychogenic nonepileptic seizures versus epilepsy. Epilepsia. 2011 Feb;52(2):292-300. doi: 10.1111/j.1528-1167.2010.02765.x. Epub 2011 Feb 7.</citation>
    <PMID>21299547</PMID>
  </reference>
  <results_reference>
    <citation>LaFrance WC Jr, Baird GL, Barry JJ, Blum AS, Frank Webb A, Keitner GI, Machan JT, Miller I, Szaflarski JP; NES Treatment Trial (NEST-T) Consortium. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized clinical trial. JAMA Psychiatry. 2014 Sep;71(9):997-1005. doi: 10.1001/jamapsychiatry.2014.817.</citation>
    <PMID>24989152</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <last_update_submitted>November 7, 2014</last_update_submitted>
  <last_update_submitted_qc>November 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rhode Island Hospital</investigator_affiliation>
    <investigator_full_name>W. Curt LaFrance Jr., M.D.</investigator_full_name>
    <investigator_title>Director, Neuropsychiatry and Behavioral Neurology</investigator_title>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>Cognitive Behavior Therapy</keyword>
  <keyword>pharmacotherapy</keyword>
  <keyword>psychogenic nonepileptic seizures</keyword>
  <keyword>pseudoseizures</keyword>
  <keyword>dissociative seizures</keyword>
  <keyword>conversion disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Dissociative Disorders</mesh_term>
    <mesh_term>Conversion Disorder</mesh_term>
    <mesh_term>Hysteria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

